FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 329:1289-1295 October 28, 1993 Number 18 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Therapy for childhood lymphoblastic leukemia has evolved during the past three decades, but key questions about what are the least toxic, most effective forms of treatment remain unanswered because of the lack of comprehensive follow-up information.

Methods To assess long-term outcome in the series of clinical trials conducted at St. Jude Hospital, we compared the results of treatment typical of four eras: exploratory combination chemotherapy (era 1, 1962 to 1966; 91 patients), regimens for the control of meningeal leukemia (era 2, 1967 to 1979; 825 patients), limited intensification of therapy (era 3, 1979 to 1983; 428 patients), and extended intensification of therapy (era 4, 1984 to 1988; 358 patients). ("Intensification" refers to strategies of systemic chemotherapy that are more aggressive than conventional ones.) The major end points were survival and event-free survival; we also calculated the relative risk of treatment failure and the rate of relapse or death after treatment ended (post-treatment failure rate).

Results The probability of event-free survival improved significantly in each successive era (P<0.001 by the log-rank test), reaching 71 percent in era 4. There was a decrease of approximately 50 percent in the risk of treatment failure from one era to the next in each subgroup of patients defined according to different combinations of the leukocyte count, race, age, and sex. Leukemia appeared to be eradicated in patients who remained in complete remission for three years or more after treatment in era 4. The incidence of death due to nonleukemic causes remained 4 to 6 percent despite the trend toward more intensive treatment. An estimated 765 patients (45 percent) are long-term survivors; most of them (80 percent) have no health problems related to leukemia or its treatment.

Conclusions The development and successful application of preventive therapy for meningeal leukemia, followed by the intensification of systemic chemotherapy, has progressively improved the rate of cure of childhood lymphoblastic leukemia, with relatively few adverse sequelae.

Source Information

From the Departments of Hematology-Oncology (G.K.R., W.M.C.) and Biostatistics (M.L.H.), St. Jude Children's Research Hospital, and the Department of Pediatrics, University of Tennessee, Memphis, College of Medicine (G.K.R., W.M.C.), both in Memphis; the M.D. Anderson Cancer Center, Houston (D.P.); and the Memorial Sloan-Kettering Cancer Center, New York (J.V.S.).

Address reprint requests to Dr. Rivera at 332 N. Lauderdale, P.O. Box 318, Memphis, TN 38101-0318.

Full Text of this Article

This article has been cited by other articles:

• Lichtman, M. A. (2008). Battling the Hematological Malignancies: The 200 Years' War. The Oncologist 13: 126-138 [Abstract] [Full Text]  
• Lee, W., Kim, S. J., Lee, S., Kim, J., Kim, M., Lim, J., Kim, Y., Cho, B., Lee, E. J., Han, K. (2005). Significance of Cerebrospinal Fluid sIL-2R Level as a Marker of CNS Involvement in Acute Lymphoblastic Leukemia. Annals of Clinical & Laboratory Science 35: 407-412 [Abstract] [Full Text]  
• Laughton, S. J., Ashton, L. J., Kwan, E., Norris, M. D., Haber, M., Marshall, G. M. (2005). Early Responses to Chemotherapy of Normal and Malignant Hematologic Cells Are Prognostic in Children With Acute Lymphoblastic Leukemia. JCO 23: 2264-2271 [Abstract] [Full Text]  
• Bader, P., Kreyenberg, H., Hoelle, W., Dueckers, G., Handgretinger, R., Lang, P., Kremens, B., Dilloo, D., Sykora, K.-W., Schrappe, M., Niemeyer, C., von Stackelberg, A., Gruhn, B., Henze, G., Greil, J., Niethammer, D., Dietz, K., Beck, J. F., Klingebiel, T. (2004). Increasing Mixed Chimerism Is an Important Prognostic Factor for Unfavorable Outcome in Children With Acute Lymphoblastic Leukemia After Allogeneic Stem-Cell Transplantation: Possible Role For Pre-Emptive Immunotherapy?. JCO 22: 1696-1705 [Abstract] [Full Text]  
• Pui, C.-H., Cheng, C., Leung, W., Rai, S. N., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Relling, M. V., Kun, L. E., Evans, W. E., Hudson, M. M. (2003). Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. NEJM 349: 640-649 [Abstract] [Full Text]  
• Marshall, G. M., Haber, M., Kwan, E., Zhu, L., Ferrara, D., Xue, C., Brisco, M. J., Sykes, P. J., Morley, A., Webster, B., Dalla Pozza, L., Waters, K., Norris, M. D. (2003). Importance of Minimal Residual Disease Testing During the Second Year of Therapy for Children With Acute Lymphoblastic Leukemia. JCO 21: 704-709 [Abstract] [Full Text]  
• Moos, P. J., Raetz, E. A., Carlson, M. A., Szabo, A., Smith, F. E., Willman, C., Wei, Q., Hunger, S. P., Carroll, W. L. (2002). Identification of Gene Expression Profiles That Segregate Patients with Childhood Leukemia. Clin. Cancer Res. 8: 3118-3130 [Abstract] [Full Text]  
• Bhatia, S., Sather, H. N., Heerema, N. A., Trigg, M. E., Gaynon, P. S., Robison, L. L. (2002). Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 100: 1957-1964 [Abstract] [Full Text]  
• Sandlund, J. T., Harrison, P. L., Rivera, G., Behm, F. G., Head, D., Boyett, J., Rubnitz, J. E., Gajjar, A., Raimondi, S., Ribeiro, R., Hudson, M., Relling, M., Evans, W., Pui, C.-H. (2002). Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 100: 43-47 [Abstract] [Full Text]  
• Woolfrey, A. E., Anasetti, C., Storer, B., Doney, K., Milner, L. A., Sievers, E. L., Carpenter, P., Martin, P., Petersdorf, E., Appelbaum, F. R., Hansen, J. A., Sanders, J. E. (2002). Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 99: 2002-2008 [Abstract] [Full Text]  
• Hoelzer, D., Gokbuget, N., Ottmann, O., Pui, C.-H., Relling, M. V., Appelbaum, F. R., van Dongen, J. J.M., Szczepanski, T. (2002). Acute Lymphoblastic Leukemia. ASH Education Book 2002: 162-192 [Abstract] [Full Text]  
• Allan, J. M., Wild, C. P., Rollinson, S., Willett, E. V., Moorman, A. V., Dovey, G. J., Roddam, P. L., Roman, E., Cartwright, R. A., Morgan, G. J. (2001). Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. USA 10.1073/pnas.191211198v1 [Abstract] [Full Text]  
• Saarinen-Pihkala, U. M., Gustafsson, G., Ringden, O., Heilmann, C., Glomstein, A., Lonnerholm, G., Abrahamsson, J., Bekassy, A. N., Schroeder, H., Mellander, L. (2001). No Disadvantage in Outcome of Using Matched Unrelated Donors as Compared With Matched Sibling Donors for Bone Marrow Transplantation in Children With Acute Lymphoblastic Leukemia in Second Remission. JCO 19: 3406-3414 [Abstract] [Full Text]  
• Wheeler, K. A., Richards, S. M., Bailey, C. C., Gibson, B., Hann, I. M., Hill, F. G. H., Chessells, J. M. (2000). Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI. Blood 96: 2412-2418 [Abstract] [Full Text]  
• Mattano, L. A. Jr, Sather, H. N., Trigg, M. E., Nachman, J. B. (2000). Osteonecrosis as a Complication of Treating Acute Lymphoblastic Leukemia in Children: A Report From the Children's Cancer Group. JCO 18: 3262-3272 [Abstract] [Full Text]  
• Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P., Buchanan, G. R. (2000). Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood 96: 1709-1715 [Abstract] [Full Text]  
• Uckun, F. M., Stork, L., Seibel, N., Sarquis, M., Bedros, C., Sather, H., Sensel, M., Reaman, G. H., Gaynon, P. S. (2000). Residual Bone Marrow Leukemic Progenitor Cell Burden after Induction Chemotherapy in Pediatric Patients with Acute Lymphoblastic Leukemia. Clin. Cancer Res. 6: 3123-3130 [Abstract] [Full Text]  
• Michel, G., Landman-Parker, J., Auclerc, M. F., Mathey, C., Leblanc, T., Legall, E., Bordigoni, P., Lamagnere, J. P., Demeocq, F., Perel, Y., Auvrignon, A., Berthou, C., Bauduer, F., Pautard, B., Schneider, P., Schaison, G., Leverger, G., Baruchel, A. (2000). Use of Recombinant Human Granulocyte Colony-Stimulating Factor to Increase Chemotherapy Dose-Intensity: A Randomized Trial in Very High-Risk Childhood Acute Lymphoblastic Leukemia. JCO 18: 1517-1524 [Abstract] [Full Text]  
• Broniscer, A., Leite, C. d. C., Lanchote, V. L., Machado, T. M. S., Cristofani, L. M. (2000). Radiation Therapy and High-Dose Tamoxifen in the Treatment of Patients With Diffuse Brainstem Gliomas: Results of a Brazilian Cooperative Study. JCO 18: 1246-1253 [Abstract] [Full Text]  
• Uckun, F. M., Gaynon, P. S., Stram, D. O., Sensel, M. G., Sarquis, M. B., Lazarus, K. H., Willoughby, M. (1999). Paucity of Leukemic Progenitor Cells in the Bone Marrow of Pediatric B-Lineage Acute Lymphoblastic Leukemia Patients with an Isolated Extramedullary First Relapse. Clin. Cancer Res. 5: 2415-2420 [Abstract] [Full Text]  
• Zecca, M., Pession, A., Messina, C., Bonetti, F., Favre, C., Prete, A., Cesaro, S., Porta, F., Mazzarino, I., Giorgiani, G., Rondelli, R., Locatelli, F. (1999). Total Body Irradiation, Thiotepa, and Cyclophosphamide as a Conditioning Regimen for Children With Acute Lymphoblastic Leukemia in First or Second Remission Undergoing Bone Marrow Transplantation With HLA-Identical Siblings. JCO 17: 1838-1838 [Abstract] [Full Text]  
• Pui, C.-H., Boyett, J. M., Relling, M. V., Harrison, P. L., Rivera, G. K., Behm, F. G., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Gajjar, A., Evans, W. E. (1999). Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. JCO 17: 818-818 [Abstract] [Full Text]  
• Boulad, F., Steinherz, P., Reyes, B., Heller, G., Gillio, A. P., Small, T. N., Brochstein, J. A., Kernan, N. A., O'Reilly, R. J. (1999). Allogeneic Bone Marrow Transplantation Versus Chemotherapy for the Treatment of Childhood Acute Lymphoblastic Leukemia in Second Remission: A Single-Institution Study. JCO 17: 197-197 [Abstract] [Full Text]  
• Mascarenhas, L., Stripecke, R., Case, S. S., Xu, D., Weinberg, K. I., Kohn, D. B. (1998). Gene Delivery to Human B-Precursor Acute Lymphoblastic Leukemia Cells. Blood 92: 3537-3545 [Abstract] [Full Text]  
• Nachman, J. B., Sather, H. N., Sensel, M. G., Trigg, M. E., Cherlow, J. M., Lukens, J. N., Wolff, L., Uckun, F. M., Gaynon, P. S. (1998). Augmented Post-Induction Therapy for Children with High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy. NEJM 338: 1663-1671 [Abstract] [Full Text]  
• Rubnitz, J. E., Pui, C.-H. (1997). Childhood Acute Lymphoblastic Leukemia. The Oncologist 2: 374-380 [Abstract] [Full Text]  
• Weisdorf, D. J., Billett, A. L., Hannan, P., Ritz, J., Sallan, S. E., Steinbuch, M., Ramsay, N. K.C. (1997). Autologous Versus Unrelated Donor Allogeneic Marrow Transplantation for Acute Lymphoblastic Leukemia. Blood 90: 2962-2968 [Abstract] [Full Text]  
• Rubnitz, J. E., Crist, W. M. (1997). Molecular Genetics of Childhood Cancer: Implications for Pathogenesis, Diagnosis, and Treatment. Pediatrics 100: 101-108 [Full Text]  
• Pratt, C. B. (1996). Pediatric Clinical Trials. The Oncologist 1: 169-172 [Abstract] [Full Text]  
• Pui, C.-H. (1995). Childhood Leukemias. NEJM 332: 1618-1630 [Full Text]  
• Pui, C.-H., Boyett, J. M., Hancock, M. L., Pratt, C. B., Meyer, W. H., Crist, W. M. (1995). Outcome of Treatment for Childhood Cancer in Black as Compared With White Children: The St Jude Children's Research Hospital Experience, 1962 Through 1992. JAMA 273: 633-637 [Abstract]  
• Uckun, F., Evans, W., Forsyth, C., Waddick, K., Ahlgren, L., Chelstrom, L., Burkhardt, A, Bolen, J, Myers, D. (1995). Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267: 886-891 [Abstract]  
• Hoelzer, D. (1993). Acute Lymphoblastic Leukemia -- Progress in Children, Less in Adults. NEJM 329: 1343-1344 [Full Text]  
• Allan, J. M., Wild, C. P., Rollinson, S., Willett, E. V., Moorman, A. V., Dovey, G. J., Roddam, P. L., Roman, E., Cartwright, R. A., Morgan, G. J. (2001). Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. USA 98: 11592-11597 [Abstract] [Full Text]